TO INNOVATIONS

SYMPOSIA THURSDAY 27 OCTOBER 2016
SYMPOSIUM 06 3 13:30-15:00 3 SESSION ROOM 1A
TUBERCULOSIS AND DIABETES COLLABORATIVE ACTIVITIES IN THE CONTEXT
OF THE END TB STRATEGY AND SUSTAINABLE DEVELOPMENT GOALS
Section: Tuberculosis, Adult & Child Lung Health
There is substantial evidence on the feasibility of integrating services for TB and diabetes mellitus (DM) in settings with dual burden
of the two diseases. However, there is limited implementation experience at larger scale.
Our objectives are to:
1) Describe progress, barriers and challenges in the implementation of TB-DM collaborative activities
2) Share promising country experiences in translating global recommendations on integrating TB and diabetes care into action
3) Identify effective models of integration in resource-constrained settings with dual burden of TB and non-communicable diseases
4) Discuss the way forward in implementing TB-DM collaborative activities, including unanswered research questions
Co-chairs: Gloria Sangiwa (United States of America), Kerri Viney (Australia)
13.30 Update on the global progress in implementing TB-diabetes collaborative activities – Anthony D Harries (United Kingdom)
13.45 TB and diabetes: promising scalable models of TB and diabetes integration in resource-poor settings with dual burden – lessons from
World Diabetes Foundation (WDF) – Anil Kapur (Denmark)
14.00 Charting the course for integrative care: five years of TB-diabetes programme progress for the Pacific –
Richard Brostrom (United States of America)
14.15 Using TB and HIV platforms for prevention and control of diabetes mellitus: successful example from Ethiopia – Degu Jerene (Ethiopia)
14.30 The TANDEM programme: understanding tuberculosis and diabetes through field studies and basic sciences – Reinout van Crevel (Netherlands)
14.45 Discussion
SYMPOSIUM 07 3 13:30-15:00 3 SESSION ROOM 3A
INTRODUCING BEDAQUILINE AND DELAMANID FOR DRUG-RESISTANT TB UNDER ROUTINE
PROGRAMME CONDITIONS: PRELIMINARY RESULTS FROM THE END TB INITIATIVE
Section: Tuberculosis
This symposium will report the first results from the UNITAID-funded End TB Initiative. Launched in April 2015, endTB will treat
2,600 multidrug-resistant (MDR-TB) patients with bedaquiline and delamanid, according to interim guidance from WHO. End TB countries
are among the first to introduce the new drugs under routine programme conditions. These experiences are key to informing adoption of bedaquiline
and delamanid in other high-burden MDR-TB countries. Presentations will highlight experiences in heterogeneous patient populations
(e.g., prisoners, patients with HIV and/or hepatitis C coinfection) and organisational strategies for ensuring safe access, such as decentralised
treatment delivery and centralised decision-making on new-drug eligibility.
Co-chairs: Carole Mitnick (United States of America), Francis Varaine (France)
13.30 Organising MDR-TB treatment with bedaquiline and delamanid: end TB in Armenia – Armen Hayrapetyan (Armenia)
13.45 Bedaquiline for the treatment of XDR-TB and pre-XDR-TB: end TB in Peru – Leonid Lecca (Peru)
14.00 Bedaquiline and delamanid for MDR-TB in a setting of high HIV coinfection: end TB in Lesotho – Llang Bridget Maama-Maime (Lesotho)
14.15 Bedaquiline and delamanid for MDR-TB in a setting of high HCV coinfection: end TB in Georgia – Tinatin Kotrikadze (Georgia)
14.30 Panel discussion: next steps for bedaquiline and delamanid for drug-resistant TB in end TB countries – Tiziana Masini (Switzerland)
14.45 Discussion
66 CONFRONTING RESISTANCE: FUNDAMENTALS TO INNOVATION - THE 47 TH UNION WORLD CONFERENCE ON LUNG HEALTH